- Home
- AGMH vs ONCO Comparison
AGMH vs ONCO Comparison
Compare AGMH & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGMH | ONCO |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 3.0M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGMH | ONCO |
|---|---|---|
| Price | $0.60 | $0.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.3M | ★ 6.7M |
| Earning Date | 10-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.48 | $0.09 |
| 52 Week High | $5.77 | $6.73 |
Technical Indicators
Market Signals| Indicator | AGMH | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 34.16 | 41.89 |
| Support Level | $0.48 | $0.09 |
| Resistance Level | $1.38 | $1.09 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 5.44 | 5.02 |
Price Performance
Historical ComparisonAbout AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is a technology company engaged in technology hardware research and development, manufacturing, assembly, and sales. Its core business segments include research and development of blockchain-oriented ASIC chips, production of high-end crypto miners for Bitcoin and other cryptocurrencies, and Fintech software services. The Company mainly derives revenue from the sales of cryptocurrency mining machines and standardized computing equipment.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.